Nivolumab plus chemotherapy is an established neoadjuvant standard of care for resectable non–small cell lung cancer. This report of the CheckMate 816 study, presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine, describes the final analysis of overall survival at 5-year follow-up in patients who received this treatment compared with chemotherapy alone.
